• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LAVA Therapeutics N.V.

    3/28/25 4:47:54 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LVTX alert in real time by email
    S-8 1 tm2510637d1_s8.htm FORM S-8

     

    As filed with the U.S. Securities and Exchange Commission on March 28, 2025

     

    Registration No. 333-

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    LAVA Therapeutics N.V.

    (Exact name of Registrant as specified in its charter)

     

     

     

    The Netherlands   84-2745484

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

         

    Yalelaan 62

    Utrecht, the Netherlands

      3584 CM
    (Address of principal executive offices)   (Zip code)

     

    Long-Term Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full titles of the plans)

     

     

     

    Stephen Hurly

    President and Chief Executive Officer

    LAVA Therapeutics N.V.

    Yalelaan 62

    3584 CM Utrecht, the Netherlands

    +31 85 016 3100

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Divakar Gupta

    Katie Kazem

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001-2157

    (212) 479-6000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 5,232,950 common shares, €0.12 nominal value per share (the “Common Shares”), of LAVA Therapeutics N.V. (the “Registrant”), consisting of:

     

    ·4,186,360 Common Shares issuable pursuant to the Registrant’s Long-Term Incentive Plan (the “2021 LTIP”), pursuant to the provisions of the 2021 LTIP providing for an automatic increase in the number of shares reserved and available for issuance under the 2021 LTIP on each of January 1, 2022, January 1, 2023, January 1, 2024, and January 1, 2025; and

     

    ·1,046,590 Common Shares issuable pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”), pursuant to the provisions of the 2021 ESPP providing for an automatic increase in the number of shares reserved and available for issuance under the 2021 ESPP on each of January 1, 2022, January 1, 2023, January 1, 2024, and January 1, 2025.

     

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

    PART II

     

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

    (a)       The contents of the Registrant’s Registration Statement on Form S-8, filed with the Commission on May 28, 2021 (File No. 333-256655);

     

    (b)       The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 28, 2025 (File No. 001-40241);

     

    (c)       The Registrant’s Current Reports on Form 8-K, filed with the Commission on February 25, 2025 and February 28, 2025 (File No. 001-40241); and

     

    (d)       The description of the Registrant’s Common Shares which is contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 28, 2025 (File No. 001-40241), including any amendment or report filed for the purpose of updating such description.

     

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    1

     

     

    ITEM 8. EXHIBITS

     

    Exhibit
    Number

     

    Description

     

    Schedule
    Form

     

    File
    Number

     

    Exhibit

     

    Filing Date

                         
    4.1   English translation of Articles of Association of LAVA Therapeutics N.V.   10-K   001-40241   3.1   March 28, 2025
                         
    5.1*   Opinion of NautaDutilh N.V., Dutch Counsel of the Registrant.                
                         
    23.1*   Consent of NautaDutilh N.V., counsel of the Registrant (included in Exhibit 5.1).                
                         
    23.2*   Consent of Independent Registered Public Accounting Firm.                
                         
    24.1*   Power of Attorney (included on the signature page of this registration statement).                
                         
    99.1   Long Term Incentive Plan and form of Award Agreement.   10-K   001-40241   10.9   March 28, 2025
                         
    99.2   2021 Employee Stock Purchase Plan.   F-1/A   333-253795   10.8   March 18, 2021
                         
    107*   Filing Fee Table                

     

     

    *     Filed herewith

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Utrecht, the Netherlands, on March 28, 2025.

     

      LAVA THERAPEUTICS, N.V.
       
      By: /s/ Stephen Hurly
        Name: Stephen Hurly
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen Hurly, Fred Powell and Amy Garabedian, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name   Title   Date
             
    /s/ Stephen Hurly  

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      March 28, 2025
    Stephen Hurly        
    /s/ Fred Powell  

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      March 28, 2025
    Fred Powell        
             
    /s/ Kapil Dhingra   Chair of the Board   March 28, 2025
    Kapil Dhingra        
             
    /s/ Jay Backstrom   Director   March 28, 2025
    Jay Backstrom        
             
    /s/ Peter Kiener   Director   March 28, 2025
    Peter Kiener        
             
    /s/ James Noble   Director   March 28, 2025
    James Noble        
             
    /s/ Christy Oliger   Director   March 28, 2025
    Christy Oliger        
             
    /s/ Mary Wadlinger   Director   March 28, 2025
    Mary Wadlinger        
             
    /s/ Karen Wilson   Director   March 28, 2025
    Karen Wilson        

     

     

    Get the next $LVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LVTX

    DatePrice TargetRatingAnalyst
    12/12/2024$11.00 → $2.00Outperform → Market Perform
    Leerink Partners
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    10/25/2022$9.00Buy
    H.C. Wainwright
    11/16/2021$24.00 → $20.00Outperform
    SVB Leerink
    8/17/2021$26.00 → $24.00Outperform
    SVB Leerink
    More analyst ratings

    $LVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

      Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. "As part of LAVA's ongoing strategic

      4/16/25 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammab

      3/28/25 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Announces Evaluation of Strategic Options

      Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused on maximizing shareholder value and has implemented cost curtailment including a workforce reduction. The Company has retained an experienced financial advisor to

      2/25/25 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Cooperatieve Gilde Healthcare Iv U.A. claimed ownership of 5,421,170 shares (SEC Form 3)

      3 - LAVA Therapeutics NV (0001840748) (Issuer)

      4/8/25 6:19:03 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wilson Karen J

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:24 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kiener Peter A

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:17 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      3/7/24 7:09:56 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

      2/14/24 4:26:22 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      11/9/23 4:37:57 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LAVA Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

      12/12/24 8:11:38 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics downgraded by JMP Securities

      JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform

      12/11/24 7:55:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on LAVA Therapeutics with a new price target

      H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00

      10/25/22 6:28:17 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Financials

    Live finance-specific insights

    See more
    • LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria

      6/1/22 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    SEC Filings

    See more
    • SEC Form DEF 14A filed by LAVA Therapeutics N.V.

      DEF 14A - LAVA Therapeutics NV (0001840748) (Filer)

      4/28/25 4:08:57 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by LAVA Therapeutics N.V.

      PRE 14A - LAVA Therapeutics NV (0001840748) (Filer)

      4/15/25 4:23:35 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by LAVA Therapeutics N.V.

      S-8 - LAVA Therapeutics NV (0001840748) (Filer)

      3/28/25 4:47:54 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

      UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca

      3/9/23 8:05:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

      UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi

      2/6/23 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

      LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas

      11/16/22 4:05:00 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care